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Abstract
The phospholamban (PLN) p.Arg14del mutation causes dilated
cardiomyopathy, with the molecular disease mechanisms incom-
pletely understood. Patient dermal fibroblasts were reprogrammed to
hiPSC, isogenic controls were established by CRISPR/Cas9, and
cardiomyocytes were differentiated. Mutant cardiomyocytes revealed
significantly prolonged Ca2+ transient decay time, Ca2+-load depen-
dent irregular beating pattern, and lower force. Proteomic analysis
revealed less endoplasmic reticulum (ER) and ribosomal and mito-
chondrial proteins. Electron microscopy showed dilation of the ER and
large lipid droplets in close association with mitochondria. Follow-up
experiments confirmed impairment of the ER/mitochondria compart-
ment. PLN p.Arg14del end-stage heart failure samples revealed perin-
uclear aggregates positive for ER marker proteins and oxidative stress
in comparison with ischemic heart failure and non-failing donor heart
samples. Transduction of PLN p.Arg14del EHTs with the Ca2+-binding
proteins GCaMP6f or parvalbumin improved the disease phenotype.
This study identified impairment of the ER/mitochondria compart-
ment without SR dysfunction as a novel disease mechanism underly-
ing PLN p.Arg14del cardiomyopathy. The pathology was improved by
Ca2+-scavenging, suggesting impaired local Ca2+ cycling as an impor-
tant disease culprit.
Keywords endoplasmic reticulum; engineered heart tissue; human-induced
pluripotent stem cells; mitochondria; phospholamban p.Arg14del
Subject Categories Cardiovascular System; Genetics, Gene Therapy &
Genetic Disease
DOI 10.15252/emmm.202013074 | Received 7 July 2020 | Revised 31 March
2021 | Accepted 7 April 2021
EMBO Mol Med (2021) e13074
Introduction
Dilated cardiomyopathy (DCM) is a common cause of severe heart
failure (HF). Mutations in several genes central to cardiomyocyte
biology have been described to cause DCM (McNally & Mestroni,
2017). The disease relevance of mutations in the gene encoding for
phospholamban (PLN) was first discovered in 2003 (Haghighi et al,
2003; Schmitt et al, 2003). PLN is a 6.1 kDa protein localized in the
membrane of the sarcoplasmic and endoplasmic reticulum (SR/ER).
It is regulated by protein kinase-mediated phosphorylation and acts
as a brake on the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
(SERCA2). In its non-phosphorylated state, PLN inhibits Ca2+ re-
uptake into the SR/ER by forming a hetero-dimer with SERCA2.
Upon phosphorylation by cAMP (PKA)- or cGMP (PKG)-dependent
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protein kinase at serine 16 or Ca2+/calmodulin-dependent protein
kinase II (CaMKII) at threonine 17, PLN dissociates from SERCA2
and forms a homo-pentamer, resulting in increased SERCA2 Ca2+
affinity and facilitated Ca2+ re-uptake into the SR/ER. Hence, PLN
acts as a key regulator at the interphase between Ca2+ homoeostasis
and force production. Overexpression of PLN in mice resulted in
reduced SR Ca2+ uptake, diminished Ca2+ transient amplitude, and
impaired left ventricular function (Kadambi et al, 1996). In contrast,
heterozygous or homozygous PLN knockout mouse models demon-
strated improved SR Ca2+ import and increased contractility (Luo
et al, 1994, 1996; Hoit et al, 1995), suggesting a close correlation
between PLN protein abundance and contractile function in mice
(Lorenz & Kranias, 1997).
In recent years, several human DCM mutations in PLN have been
discovered. PLN p. Leu39 results in expression of a truncated unstable
PLN protein. In cellular expression systems, the PLN p. Leu39stop
mutation leads to a maximally active SERCA2a pump. Heterozygous
and homozygous mutant carriers exhibit severe cardiomyopathy
(Haghighi et al, 2003). Importantly, substantial species differences
exist regarding the disease outcome of PLN deficiency. While benefi-
cial effects resulted from PLN ablation in mice, the absence of PLN
protein in patients was associated with severe cardiomyopathy
(Haghighi et al, 2003). PLN p. Arg9Leu and PLN p. Arg9His mutations
potentially led to altered interaction with PKA and abnormal phospho-
rylation of PKA substrate proteins (Medeiros et al, 2011). Finally, PLN
p. Arg9Cys, PLN p. Arg25Cys, and PLN p. Arg14del were described to
exert super-inhibitory effects on SERCA2a activity (Schmitt et al,
2003; Haghighi et al, 2012; Liu et al, 2015).
PLN p. Arg14del was first identified in a greek family (Haghighi
et al, 2006) and subsequently identified as a DCM founder mutation
in the Netherlands, where this mutation is accounting for up to 15%
of all DCM cases (Van Der Zwaag et al, 2012). Clinically, PLN p.
Arg14del mutation carriers present with left ventricular dysfunction
and dilation and malignant ventricular arrhythmia. Transgenic over-
expression of PLN p. Arg14del in wild-type (WT) mice resulted in
the development of cardiomyopathy and reduced survival. SR
preparations from PLN p. Arg14del overexpressing mice showed a
small, but significant rightward shift of the SR Ca2+-uptake rate,
suggesting that PLN p. Arg14del, similar to the other mutant forms,
acts as a super-inhibitor of SERCA2a (Haghighi et al, 2006). The
effect was shown to depend on the presence of WT PLN, because
transgenic overexpression of PLN p. Arg14del in a PLN knockout
mouse model did not alter Ca2+ re-uptake kinetics (Haghighi et al,
2012). Of note, normal SR Ca2+ uptake in this model was associated
with a similarly severe DCM phenotype, indicating that mechanisms
distinct from abnormal SR Ca2+ cycling contribute to the pathology
of PLN p. Arg14del cardiomyopathy. Homozygous PLN p. Arg14del
knock-in mice exhibited a DCM phenotype, with cardiac dilation
and fibrosis, accompanied by contractile dysfunction, and arrhyth-
mia (Eijgenraam et al, 2020).
It is difficult to elucidate disease mechanisms exerted by PLN
mutations in mice. This is exemplified by the antithetic effects
observed in response to complete PLN deletion, which relates to the
lower chronotropic reserve of the mouse versus the human heart
(Kranias & Hajjar, 2012). This limitation emphasizes the necessity
for human-based studies to unravel disease mechanisms associated
with PLN p. Arg14del. Histological analysis of explanted human
hearts and left ventricular biopsies from PLN p. Arg14del heart
failure (HF) patients showed dense perinuclear globular PLN-
positive aggregates as a disease-specific characteristic (te Rijdt
et al, 2016, 2017). Human-induced pluripotent stem cell-derived
cardiomyocytes (hiPSC-CMs) from a DCM patient carrying a PLN p.
Arg14del mutation revealed a significantly higher spontaneous beat-
ing frequency, irregular Ca2+ transients, and lower force develop-
ment than respective isogenic controls (Karakikes et al, 2015;
Stillitano et al, 2016). The authors concluded that the phenotype
was compatible with super-inhibition of SERCA2a by PLN p.
Arg14del. However, the higher caffeine-induced Ca2+ transient
amplitude in PLN p. Arg14del cardiomyocytes is difficult to recon-
cile with super-inhibition of SERCA2a and indicative of other, yet
unknown consequences of PLN p. Arg14del.
The present study aimed at shedding new light on the molecular
disease mechanisms evoked by the PLN p. Arg14del mutation and
involved: (i) establishment of a patient-specific PLN p. Arg14del
hiPSC line and a respective repaired isogenic control; (ii) phenotypi-
cal and functional characterization of hiPSC-CM in a three-
dimensional engineered heart tissue (EHT) format showing
preserved SR function; (iii) proteomic and RNA-seq analysis
suggesting impairment of the ER/mitochondria compartment; (iv)
confirmation by histology of end-stage HF patient and non-failing
human heart samples; and (v) improvement of the disease pheno-
type by heterologous expression of Ca2+ scavengers.
Taken together, the data suggest that PLN p. Arg14del cardiomy-
opathy is associated with functional alterations in the ER/mitochon-
dria compartment with improvement by Ca2+ scavenging.
Results
Clinical profile and hiPSC derivation
A female 31-year-old DCM patient was identified as a carrier of a
heterozygous PLN p. Arg14del mutation. The patient was diagnosed
with DCM at the age of 28 years and presented clinically with HF
symptoms and ventricular arrhythmia. Her mother was also identi-
fied as a PLN p. Arg14del mutation carrier and diagnosed with DCM
(Fig 1A). Patient-derived dermal fibroblasts were reprogrammed to
hiPSC, and a respective isogenic control hiPSC line (PLNic) was
generated by CRISPR/Cas9 technology (Fig 1B). Pluripotency was
demonstrated by immunofluorescence (IF) staining for Oct-4A or
TRA-1-60. G-banding demonstrated a normal karyotype
(Appendix Fig S1A–E). No off-target effects after CRISPR/Cas9
genome editing were detected by sequencing the 10 most likely off-
target loci (Appendix Fig S1F). Cardiomyocytes from PLN p.
Arg14del (78  15% positive for cTNT; mean  SD, n = 9 batches
from two clones) and PLNic hiPSC (80  16% positive for cTNT;
mean  SD, n = 9 batches from two clones) were differentiated,
and hiPSC-CMs were cultured in two-dimensional (2D) and three-
dimensional (3D, engineered heart tissue; EHT) format. Quantitative
RT–PCR revealed no detectable PLN p. Arg14del mRNA in PLNic
hiPSC-CM and approximately 50% expression of both, PLN WT and
p. Arg14del mRNA, in PLN p. Arg14del hiPSC-CM (Fig 1C). Analysis
of total RNA from left ventricular samples obtained from two inde-
pendent DCM patients carrying a heterozygous PLN p. Arg14del
mutation revealed a ~1:1 ratio of PLN WT and p. Arg14del mRNA
(Fig 1D). IF analysis of 2D hiPSC-CM revealed similar perinuclear
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PLN and SERCA2 protein localization in both genotypes, albeit
staining was weaker in PLN p. Arg14del (Fig 1E, Appendix Fig S1G
and H). Western blot analysis of EHTs showed lower abundance of
monomeric PLN protein in PLN p. Arg14del and PLNic versus
human non-failing heart (NFH), with no difference in the penta-
meric PLN form (Fig 2A and B). The close proximity between PLN
p. Arg14 and PLN p. Ser16, the phosphorylation target site, raised
the question, whether the response to the b-adrenoceptor agonist
isoprenaline (ISO) was altered in PLN p. Arg14del. Western immu-
noblot analysis showed that ISO significantly enhanced band inten-
sity of the pentameric pSer16 PLN only for PLNic, suggesting lower
ISO-mediated phosphorylation of PLN p. Arg14del (Fig 2C and D).
Functionally, ISO exerted a positive inotropic (Force PLNic: +61%,
PLN p. Arg14del: +64%) and lusitropic effect (relaxation time
PLNic: 7%, PLN p. Arg14del: 11%), without apparent dif-
ferences between genotypes (Fig 2E and F, Appendix Fig S2A). This
showed that despite lower ISO-mediated phosphorylation in PLN p.
Arg14del, the canonical inotropic and lusitropic force responses to
ISO remained unchanged.
Contractile force
Contractile analysis in EHTs (6 differentiation batches; two different
clones) revealed that PLN p. Arg14del EHTs developed significantly
lower force and a higher beating frequency than PLNic assessed at
two different time points (Fig 3A–D, Movies EV1 and EV2). Force
analysis under electrical stimulation (2 Hz) confirmed lower forces
of PLN p. Arg14del EHTs and showed no apparent differences in
time to peak (TTP-80%) and relaxation time (RT80%) (Fig 3E, G, H
and I). Normalized average contraction peaks revealed a significant
prolongation of the relative relaxation time for PLN p. Arg14del
(RT80%/force amplitude, +170%, Fig 3F and J). Overall, the data
demonstrated that PLN p. Arg14del EHTs beat faster, develop 50%





Figure 1. HiPSC line derivation and validation.
A Pedigree of the patient family. Arrow: Index patient; index patient and mother are PLN p.Arg14del mutation carriers and were diagnosed with DCM.
B Sequencing of PLN patient-derived hiPSC (PLN p.Arg14del) and isogenic controls (PLNic) to confirm CRISPR/Cas9-mediated gene correction. Red box indicates
codon for Arg14, and blue box indicates silent PAM (protospacer adjacent motif) mutation.
C, D Relative PLN transcript level (normalized to ACTN2 and PLNic wt+mt) with PCR primers amplifying PLN wild type (wt) and p.Arg14del (mt), only wt or only
p.Arg14del (mt). (C) Analysis of PLNic (n = 9 EHTs from 5 batches, each replicate consists of a pool of 1–2 EHTs from separate batches) and PLN p.Arg14del (n = 9
EHTs from 3 batches, each replicate consists of a pool of 2–4 EHTs from separate batches) EHTs, mean  SEM. (D) Analysis of PLN p.Arg14del EHTs (n = 9 EHTs
from 3 batches, each replicate consists of a pool of 2–4 EHTs from separate batches) and two independent failing heart patient samples from heterozygous PLN
p.Arg14del mutation carriers (each n = 1 RNA sample, 2 separate PCR analysis), mean  SEM.
E Immunofluorescence of 2D hiPSC-CM from each genotype with antibodies against PLN (red) and SERCA2 (green) and DAPI staining of nuclei (blue); scale bar
20 µm.
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Ca2+ transient analysis
Analysis of Ca2+ transients in Fura 2-loaded 2D hiPSC-CM showed a
significant prolongation of late Ca2+ decay time (DT) in PLN p.
Arg14del (DT80% PLNic: 0.337  0.01 s, n = 25; PLN p. Arg14del:
0.437  0.02 s, n = 24). Notably, this was not associated with dif-
ferences in Ca2+ transient amplitude, diastolic Ca2+ content, or Ca2+
transient decay tau (Fig 4A–E), nor was the caffeine-induced Ca2+
transient amplitude altered (Appendix Fig S2B–F). The late DT
prolongation was compatible with the late relaxation deficit, but
normal caffeine-induced Ca2+ transient amplitude argued against
gross abnormalities of SR function in PLN p. Arg14del EHTs.
Ca2+ induced irregular beating pattern
In patients, PLN p. Arg14del DCM is often accompanied by severe
arrhythmia. Indeed, PLN p. Arg14del displayed an occasional
irregular beating pattern (IBP) under standard cell culture condi-
tions (Fig 4F). To allow quantification and to study the dependence
of IBP on Ca2+ loading, EHT contractility was recorded for 9 h in
Tyrode’s solution supplemented with 1.0, 1.8, or 3.0 mM extracellu-
lar Ca2+. RR scatter (interdecile range of mean beat-to-beat distance)
in PLNic EHTs was significantly higher at 1.8 mM than 1.0 mM
Ca2+ and showed a Ca2+ concentration-dependent increase in IBP in
PLN p. Arg14del EHTs. The RR scatter at 1.8 and 3.0 mM was signif-
icantly higher in PLN p. Arg14del than in PLNic EHTs (Fig 4G),
corroborating a Ca2+-dependent IBP-phenotype in PLN p. Arg14del.
Proteomic analysis, quantification, and function of mitochondria,
ultrastructural analysis
Given the apparent discrepancy between severe contractile
dysfunction and IBP in PLN p. Arg14del despite the absence of
changes in intracellular Ca2+ transients and SR Ca2+ loading, EHTs
A C E
B D F
Figure 2. PLN expression profile and response to isoprenaline.
A Western immunoblot analysis of total PLN in non-failing heart tissue (NFH), PLNic, and PLN p.Arg14del EHTs. Pentameric (PM) and monomeric (MM) form of PLN
under boiled (B) and non-boiled (NB) conditions.
B PLN protein quantification of PM and MM forms under non-boiled condition. NFH (n = 5 protein samples from two different donor hearts), PLNic (n = 8, each
replicate consists of a pool of 3 EHTs from three different separate batches), and PLN p.Arg14del (n = 8, each replicate consists of a pool of 3–4 EHTs from three
different separate batches). Loading was normalized to a-actinin. One-way ANOVA of PM and MM forms with Tukey’s post-test, mean  SEM, * P < 0.05.
C Western immunoblot analysis of PLN pSer16 MM and PM in PLNic and p.Arg14del EHTs (non-boiled) in the absence and presence of isoprenaline (ISO; 100 nM,
loading was normalized to a-actinin).
D PLN pSer16 quantification of PM and MM form (non-boiled; loading was normalized to a-actinin). PLNic  isoprenaline (n = 8, each replicate consists of a pool of
3–4 EHTs from three different separate batches) and PLN p.Arg14del  isoprenaline (n = 8, each replicate consists of a pool of 3–4 EHTs from three different
separate batches). One-way ANOVA of PM and MM forms with Sidak’s post-test, *P < 0.05. Mean  SEM.
E, F Force (E) and relaxation time (RT) (F) of PLNic and PLN p.Arg14del EHTs in Tyrode’s solution (Ca2+ 1.8 mM), Tyrode’s solution (EC50 [Ca
2+]: PLNic: 0.4–0.6 mM, PLN
p.Arg14del: 0.7–0.8 mM), in the presence of ISO (100 nM) or carbachol (10 µM); PLNic (n = 27 EHTs from 4 batches), PLN p.Arg14del EHTs (n = 19 EHTs from 3
batches), mean  SEM, one-way ANOVA for PLNic or PLN p.Arg14del EHTs with Tukey’s post hoc test, *P < 0.05. The data are representative of n = 6 independent
experiments.
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of both genotypes were subjected to label-free proteomic analysis
in the search for alternative mechanisms. In total, 2,843 proteins
were detected and 1,576 proteins differed significantly between
PLNic and PLN p. Arg14del (FDR < 0.05; Dataset EV1). Principal
component analysis showed separate clustering of PLNic from PLN
p. Arg14del for all replicates (Fig 5A). Unsupervised hierarchical
clustering confirmed differences between PLNic and PLN p.
Arg14del (Appendix Fig S3A). Enrichment pathway analysis identi-
fied differences in KEGG pathways related to ribosome, protein
processing in endoplasmic reticulum (ER), lysosome, phagosome,
peroxisome, glutathione metabolism, and energy metabolism/mito-
chondria between PLNic and PLN p. Arg14del (Fig 5B and C;
Tables EV1 and EV2). Differently abundant ER proteins included
Ca2+-binding chaperones and proteins involved in protein folding,
N-glycosylation, and ubiquitination. Congruent with the observed
alteration of mitochondrial proteins, quantitative analysis of mito-
chondrial DNA (mtDNA, Mt-ND1, 2) demonstrated 3.3-fold lower
values for PLN p. Arg14del (Appendix Fig S3B). Co-expression
network analysis of metabolism-related proteins revealed over-
representation of carbohydrate, fatty acid, lipid, and one-carbon
substrate metabolism in PLN p. Arg14del (Appendix Fig S3C),
supported by differential abundance of metabolic key enzymes
such as 50 AMP-activated protein kinase (AMPK) and glycogen
phosphorylase (Dataset EV1).
Interestingly, constituent proteins of the ER/mitochondria
contact site that ascertain unperturbed ER-mitochondrial crosstalk,
namely calnexin (Lynes et al, 2013; Bravo-Sagua et al, 2016), the
voltage-dependent anion-selective channel (Szabadkai et al, 2006),
and mitofusin-2 (Papanicolaou et al, 2011; Chen et al, 2012), were
among the lower abundant proteins in PLN p. Arg14del. Also PLN,
but not SERCA, was lower abundant in PLN p. Arg14del, supporting
our previous IF data (Fig 1E; Appendix Fig S3D–K). To investigate
whether differences in mitochondrial number and shape were
detectable in PLN p. Arg14del, ultrastructural analysis of hiPSC-CM
EHTs was performed. Indeed, transmission electron microscopy
(TEM) confirmed lower abundance of mitochondria in PLN p.
Arg14del, large lipid droplets in close association with mitochondria
and pathologically dilated ER structures (Fig 5D and E). Accumula-
tion of perinuclear lipid droplets in PLN p. Arg14del was subse-
quently confirmed by IF analysis of 2D hiPSC-CM by BODIPYTM
staining (Fig 5F) and suggests disturbed lipid transfer via ER/mito-
chondria contact sites (Janer et al, 2016).
Western immunoblot analysis was used as alternative methodol-
ogy to validate the differential abundance of candidate proteins
A C E G I
B D F H J
Figure 3. Analysis of contractile force in EHTs.
A–D Force and frequency analysis of spontaneous force development and beating frequency in EHTs on days 20/21 (A, B) and day 30 (C, D) of EHT development, PLNic:
n = 70/67 EHTs from 5–6 batches (as indicated in the figure), PLN p.Arg14del: n = 77/65 EHTs from 6 batches, mean  SEM, Mann–Whitney U-test, *P < 0.05. The
data are representative of n = 10 independent experiments for days 20/21 and n = 9 independent experiments for day 30. Force: days 20/21 PLNic: 0.11  0.007
mN; p.Arg14del: 0.06  0.003 mN; and day 30 PLNic: 0.13  0.005 mN; p.Arg14del: 0.07  0.005 mN; frequency: days 20/21 PLNic: 81  2 BPM; p.Arg14del:
98  2 BPM; and day 30 PLNic: 77  2 BPM; p.Arg14del: 88  3 BPM.
E–J Contractility analysis of electrically stimulated EHTs (2 Hz) on days 21  3 of EHT development. Absolute (E) and relative (F) (normalized to peak maximum)
average contraction peaks. Analysis of force (G), time to peak (H), relaxation time (I), and relaxation time/force ratio (J), PLNic: 0.14  0.009 mN, n = 21, 5 batches;
PLN p.Arg14del: 0.07  0.005 mN, n = 35, 5 batches, mean  SEM, unpaired two-sided Student’s t-test, *P < 0.05. The data are representative of n = 8
independent experiments.
ª 2021 The Authors EMBO Molecular Medicine e13074 | 2021 5 of 19
Friederike Cuello et al EMBO Molecular Medicine
observed in the proteomic screen. Signal intensities for galectin-3
and SAFB-like transcription modulator (SLTM) were significantly
higher in PLN p. Arg14del. LIM and cysteine-rich domains 1
(LMCD1) and calnexin exhibited weaker band intensities in PLN p.
Arg14del. No difference was detected for reticulocalbin-3. In addi-
tion, phosphorylation of pyruvate dehydrogenase (PDH) at pS293
indicative of enzyme inhibition and phosphorylation of AMPK at
pThr172 indicative of enzyme activation were higher in PLN p.
Arg14del, pointing to alteration in ER-mitochondria crosstalk (Fig
EV1A and B). The reduction in calnexin protein levels shown by
Western immunoblot analysis was supported by weaker IF staining
and a loss of the perinuclear localization of calnexin in PLN p.
Arg14del 2D hiPSC-CM (Fig EV1C).
In order to investigate whether the reduced mitochondrial
content and the discrepant metabolic profile in PLN p. Arg14del
were paralleled by impairment of mitochondrial respiration,
Seahorse experiments were performed in 2D hiPSC-CM. PLN p.
Arg14del revealed lower oxygen consumption rate under baseline
and experimental conditions, resulting in lower values for basal and
maximal respiration rate and lower ATP production (Fig 6A–D). In
line with this, fluorometric detection of the oxidation of a dichloro-
hydrofluorescein probe revealed significantly higher steady state
levels of reactive oxygen and nitrogen species (ROS/RNS) in PLN p.
Arg14del (Fig 6E). IF staining of 2D hiPSC-CM of both genotypes
with an established marker of oxidative stress, 8-hydroxydeoxyguanosine
(8-OHdG), revealed enhanced signal intensity in PLN p. Arg14del
(Fig 6F). This observation was supported by enhanced detection of
derivatized cellular protein carbonylation in PLN p. Arg14del by
Western immunoblotting (Fig 6G). This finding supports our
proteomic data that suggested a stronger representation of the
KEGG pathway for glutathione metabolism (Table EV1) and a
higher abundance of superoxide dismutase (SOD1) in PLN p.
Arg14del (Dataset EV1) suggesting oxidative stress as a confounder
in PLN p. Arg14del cardiomyopathy.
Transcriptomic analysis
To investigate differences in the transcriptomic profile of PLNic
versus PLN p. Arg14del during the differentiation to hiPSC-CM,
RNA sequencing analysis was performed at specific stages of the dif-
ferentiation procedure. Principal component analysis on day 0 (un-
differentiated hiPSC), day 3 (mesodermal progenitors), day 8
(cardiac progenitors), and day 15 (early CM) revealed close cluster-
ing of both genotypes according to the time point of differentiation
(Appendix Fig S4C). Analysis of prototypical differentiation markers
(Fu et al, 2018) (Branco et al, 2019) revealed stage-specific marker
expression in both genotypes, but lower expression of cardiac mark-
ers in PLN p. Arg14del on day 15 (Appendix Fig S4A and B).
Accordingly, a number of cardiac KEGG pathways were enriched in
PLNic on day 15 (Appendix Fig S4D and E). Notably, ER/
A
F G
B C D E
Figure 4. Ca2+ transient analysis in Fura 2-loaded 2D hiPSC-CM.
A–E Average Ca2+ transient peak (A), Ca2+ transient amplitude (B), diastolic Ca2+ (C), time to decay 80% (D), and Ca2+ decay tau (E); PLNic: n = 25 hiPSC-CM from 2
batches and PLN p.Arg14del: n = 24 hiPSC-CM from 2 batches, mean  SEM, Mann–Whitney U-test, *P < 0.05.
F Representative EHT recording.
G RR scatter (surrogate for irregular beating pattern, IBP, interdecile range of mean beat-to-beat distance) of PLNic and PLN p.Arg14del EHT at 1.0, 1.8, and 3.0 mM
extracellular Ca2+ concentration, incubation time 9 h, recording time 50 s, PLNic: 1.0 mM: n = 24/3, 1.8 mM: n = 32/4, 3.0 mM: n = 41/5 (EHT/batches), PLN
p.Arg14del: 1.0 mM: n = 15/2, 1.8 mM: n = 24/3, 3.0 mM: n = 23/3 (EHT/batches), mean  SEM, two-way ANOVA (comparing hiPSC lines and Ca2+ concentrations
(but not time points)) with Tukey’s post hoc test, *P < 0.05. The data are representative of n = 5 independent experiments.
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mitochondria contact site markers (e.g., CANX, VDAC 1-3, RCN-3,
MFN2) showed lower expression and ITPR2 showed higher expres-
sion in PLN p. Arg14del on day 15 (Appendix Fig S5A–I). ER stress
response and fetal gene program marker genes did not differ
between genotypes.
Immunohistochemistry in human heart failure samples
Immunohistochemistry was employed to investigate whether defects
in the ER/mitochondria compartment that were identified in the
present study were also relevant and typical for human PLN p.
Arg14del end-stage HF patients. Autopsy and explanted left ventric-
ular samples from NFH, ischemic HF (IHF), and PLN p. Arg14del-
related end-stage HF hearts were analyzed (Fig 7). PLN staining
revealed the presence of perinuclear aggregates for PLN p. Arg14del,
as previously reported (te Rijdt et al, 2016, 2017). RCN-3, an ER
Ca2+-binding chaperon protein that acts as a negative regulator of
collagen production (Tsuji et al, 2006; Martınez-Martınez et al,
2017), was low abundant in PLN p. Arg14del (Dataset EV1). PLN
end-stage HF showed significantly more RCN-3-positive perinuclear
aggregates than NFH or IHF samples (Fig 7A and C), suggesting that
perinuclear aggregates linked to the ER. Notably, also for 8-OHdG,
significantly more dotted perinuclear staining was detected in PLN
p. Arg14del (Fig 7A and B). Two other dysregulated proteins in PLN
p. Arg14del EHTs, which were not localized to the ER/mitochon-
drial compartment, did not show this perinuclear staining pattern:
LMCD1, a sarcomeric Z-disk hypertrophy-mediating protein (Frank
et al, 2010), was downregulated in PLN p. Arg14del EHTs and
revealed an enhanced mosaic-like pattern with different cellular
staining intensities particularly in PLN and to a lesser extent in IHF.
SLTM, a pro-apoptotic nuclear protein (Chan et al, 2007), that was
more abundant in PLN p. Arg14del EHTs revealed a nuclear staining
pattern in PLN p. Arg14del, non-failing and IHF samples (Fig 7A).
The perinuclear staining pattern of RCN-3 and 8-OHdG suggests ER
alterations associated with oxidative stress in PLN p. Arg14del end-
stage HF hearts.
Ca2+ scavenging
Complementary to Ca2+ transient measurements in 2D hiPSC-CM
(Fig 4A–D), analysis was complemented in 3D EHT format after





Figure 5. Proteomic analysis, transmission electron microscopy.
A Principal component analysis (PCA) of PLNic (blue, n = 12) and PLN p.Arg14del (red, n = 10) EHTs based on their proteomic profiles. Each dot represents one EHT.
B Significantly enriched pathways of up- and downregulated proteins.
C Volcano plot of log2 fold changes (PLNic versus PLN p.Arg14del) and log10 of the P-values with color-coded significance levels.
D, E Transmission electron microscopy of PLNic and PLN p.Arg14del EHTs; mf: myofilaments, Z: Z-line, rib: ribosome, m: mitochondria, sER: smooth endoplasmic
reticulum, rER: rough endoplasmic reticulum, dER: dilated endoplasmic reticulum, N: nucleus, and L: lipid droplet.
F Immunofluorescence analysis of 2D hiPSC-CM from PLNic and PLN p.Arg14del with BODIPYTM lipid staining (red), a-actinin (green), and DAPI staining for nuclei
(blue); scale bar 20 µm.
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Similarly, no difference in Ca2+ transient amplitude was detected
(Appendix Fig S6A–J). For PLNic, force development was slightly
lower in the presence of GCaMP6f, an expected consequence due to
its function as a Ca2+ buffer. Surprisingly, contractile force improved
for PLN p. Arg14del in the presence of GCaMP6f (PLN p. Arg14del
force without GCaMP6f: 49% of PLNic value, Fig 3E; PLN p.
Arg14del force with GCaMP6f: 81% of PLNic value, Appendix Fig
S6F). This chance-finding suggested functional improvement of the
PLN p. Arg14del phenotype by GCaMP6f-mediated Ca2+ scavenging.
To support this observation, experiments were repeated using
another Ca2+-binding protein, the EF-hand protein parvalbumin
(Wang & Metzger, 2008). HiPSC-CMs in 2D and 3D format were
transduced with an empty control-, GCaMP6f-, or parvalbumin-
encoding virus. IF analysis of 2D hiPSC-CM suggested no difference
in PLN and SERCA2 protein expression nor localization and con-
firmed heterologous expression of both Ca2+ scavenging proteins.
While heterologous expression of GCaMP6f localized uniformly
throughout the cell, a large fraction of the expressed parvalbumin
resided in the nucleus (Appendix Fig S7A–E). In the control-
transduced groups, phosphorylation of PDH at pS293 and AMPK at
pThr172 was significantly higher in PLN p. Arg14del than in PLNic
(Fig 8A–D). In PLN p. Arg14del, expression of GCaMP6f or parval-
bumin significantly reduced phosphorylation levels compared to
control-transduced hiPSC-CM EHTs. Band intensities for PLN and
SERCA2 remained unaltered (Appendix Fig S8A–D). Expression of
GCaPM6f in PLN p. Arg14del was associated with significantly
higher force development, but not for parvalbumin (Fig 8E). The
small effect on force development in response to parvalbumin
expression could be explained by the mainly nuclear localization of
parvalbumin. Analysis of ER/unfolded protein response (UPR)
stress response markers revealed higher gene expression of protein
disulfide isomerase family A member 4 (PDIA4) and the ER chaper-
ones BIP and HYOU1 in PLN p. Arg14del. BIP and HYOU1 expres-
sion was reduced by Ca2+ scavenging in PLN p. Arg14del (Fig 8F–
H). Other prototypical ER/UPR stress markers or fetal gene program
marker did not reveal convincing differences between genotypes
(Appendix Fig S8E–G, Appendix Fig S9A–D). This observation was
in conjunction with the respective proteomic data (Appendix Fig
S9E–G). IF staining for 8-OHdG revealed no signals for PLNic in all
virus groups. In contrast, enhanced 8-OHdG signals were detectable
for PLN p. Arg14del with no impact in response to Ca2+ scavenging
(Fig 8I and J). Proximity ligation assays (PLAs) were performed to
A
F G
B C D E
Figure 6. Mitochondrial respiration and detection of oxidative stress.
A Oxygen consumption rate in PLNic versus PLN p.Arg14del. Mean  SEM.
B–D Quantification of basal respiration (B), maximal respiration (C) and ATP production (D). Mean  SEM, n = 6 biological replicates (each biological replicate
represents the average of 12 wells of a 96-well Seahorse plate), Mann–Whitney U-test, *P < 0.05.
E Fluorometric detection of ROS content in complete medium supernatant or lysed cells after 24 h of EHT culture, n = 8 EHTs, each circle: Mean of 6 technical
replicates, mean  SEM, Mann–Whitney U-test,*P < 0.05.
F Immunofluorescence of 2D hiPSC-CM from PLNic and PLN p.Arg14del for PLN (red), 8-hydroxydeoxyguanosine (8-OHdG; green) and DAPI-stained nuclei; scale bar
20 µm.
G Western immunoblot analysis of 2D hiPSC-CM from PLNic and PLN p.Arg14del with an anti-2,4-dinitrophenylhydrazine antibody (DNPH) that detects the presence
of carbonyl groups modified by 2,4-dinitrophenylhydrazine as a surrogate marker of irreversibly oxidized proteins, n = 8 replicates per genotype, cMyBP-C was
used as a loading control.
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investigate the proximity of ER-mitochondrial contact sites by using
a combination of antibodies that detect VDAC1 that localizes to the
outer mitochondrial membrane and IP3R that localizes to the ER.
This revealed no differences in PLNic between control-, GCaMP6f-,
or parvalbumin-transduced hiPSC-CM (Fig EV2A–C). Thapsigargin
exposure that provokes a stress response led to an increase in the
PLA signal intensity for each condition in the PLNic group. The PLN
p. Arg14del control-transduced hiPSC-CM revealed similar signal
intensity as the PLNic control group. Transduction with the
GCaMP6f or parvalbumin virus increased PLA signal intensity
substantially, suggesting dynamic alterations within the ER-
mitochondrial compartment. Interestingly, stress induced by thapsi-
gargin exposure decreased PLA signal intensity for all PLN p.
Arg14del conditions, in line with a lower tolerance to ER stress
compared to PLNic (Fig EV2A and B). TEM analysis for the different
virus conditions confirmed low abundance of mitochondria and the
appearance of dilated and elongated structures of the ER in PLN p.
Arg14del. In PLNic, no overt morphological differences in cellular
organelles were detectable. In contrast, PLN p. Arg14del showed
higher number of mitochondria after heterologous expression of
GCaMP6f or parvalbumin. Additionally, in GCaMP6f expressing
PLN p. Arg14del EHTs, no dilated ER structures were detectable
(Fig EV3).
In aggregate, PLN p. Arg14del cardiomyopathy was successfully
modeled in hiPSC-CM with reproduction of disease-specific features.
This allowed us to study and subsequently decipher a novel path-
omechanism of PLN p. Arg14del cardiomyopathy. Key aspects were
validated in human end-stage PLN p. Arg14del HF samples.
Improvement by Ca2+ scavenging points to the relevance of Ca2+
handling abnormalities.
Discussion
Heterozygous PLN p. Arg14del mutation is an established cause of
DCM and severe HF. The molecular mechanisms that govern disease
development are subject of debate and incompletely understood.
Super-inhibitory effect of PLN p. Arg14del on SERCA2a function
was suggested as the major underlying molecular disease mecha-
nism, despite the observation that PLN p. Arg14del overexpression
in PLN KO mice induced a DCM phenotype without affecting SR
function (Haghighi et al, 2012). The present study showed that SR
function of hiPSC-CM or derived EHTs was unaffected by the pres-
ence of PLN p. Arg14del as reflected by unchanged Ca2+ transient
amplitude, caffeine-induced Ca2+ release, and a canonical lusitropic
response to ISO. Small prolongation of relaxation and Ca2+ decay
time in PLN p. Arg14del hiPSC-CM or EHTs were observed, but the
magnitude of the changes did not match the large decrease in
contractile force and the Ca2+-dependent beating irregularities as a
surrogate of arrhythmia. These observations raised the question,
which alternative mechanisms could connect small defects in late
Ca2+ removal from the cytosol and Ca2+ induced IBP with low force
development. Results from the present study proposed alteration of
the ER and mitochondria, altered post-translational modifications of
key metabolic enzymes such as PDH and AMPK, perinuclear lipid
accumulation, oxidative stress, mitochondrial dysfunction, and
degeneration. These molecular abnormalities resembled a pathologi-
cal pattern previously reported to reflect disturbed ER/mitochondria
contact sites. Constitutive IP3R-mediated Ca
2+ release from the ER to
the mitochondria ascertains unperturbed mitochondrial function
and cellular bioenergetics. The key enzyme in the mitochondria that
catalyzes the formation of acetyl-CoA as well as flavin and
A B
C
Figure 7. Immunohistochemistry of non-failing heart (NFH), ischemic cardiomyopathy heart failure (ICM), and PLN p. Arg14del end-stage heart failure (PLN).
A 8-Hydroxy-20-deoxyguanosine (8-OHdG), reticulocalbin-3 (RCN3), LIM and cysteine-rich domains protein 1 (LMCD1), and SAFB-like transcription modulator (SLTM).
Scale bar 100 µm.
B, C Quantification of aggregates for 8-OHdG staining (B) (n = 3 different human hearts for NFH and PLN, n = 2 human hearts for IHF, 4–5 areas per heart) and RCN-3
(C) (n = 3 different human hearts for NFH, IHF, and PLN, 4–5 areas per heart) sections. One-way ANOVA with Tukey’s post hoc test for multiple comparison,
*P < 0.05, mean  SEM.
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nicotinamide adenine dinucleotide from pyruvate is PDH. PDH
activity is inhibited by phosphorylation via pyruvate dehydrogenase
kinase 1, when IP3-receptor-mediated Ca
2+ current is reduced
(Cardenas et al, 2010). Indispensable for the integrity of the Ca2+-
flux to sustain the crosstalk between ER and mitochondria is the
close proximity between these organelles. Various experimental
studies provided evidence that mitofusin-2 functions as a key
component that tethers the mitochondria to the ER, thereby ensur-
ing functional organelle linkage. Alteration of ER/mitochondria
contact sites in mouse cardiomyocytes corroborated these mechanis-
tic observations and described oxidative stress, mitochondrial insuf-
ficiency and degradation, hypo-contractility and cardiomyopathy
with preserved Ca2+ transient amplitude as an immediate result (de
Brito & Scorrano, 2008; Papanicolaou et al, 2011; Chen et al, 2012;
Chen & Dorn, 2013; Song et al, 2014). Several features of ER/mito-
chondria contact site disruption were identified in the present study:
reduced abundance of constituent components of the contact site,
stronger phosphorylation of PDH, perinuclear lipid accumulation,
and oxidative stress. Putting this in context with the established
function of SERCA2/PLN in both, SR and ER, this impairment of
inter-organelle communication between ER and mitochondria
argues strongly for a previously ignored contribution of the ER to
the PLN p. Arg14del cardiomyopathy.
The ER is an extension of the nuclear membrane and shows a
perinuclear subcellular localization. Therefore, it is not surprising to
observe perinuclear PLN-positive aggregates in PLN p. Arg14del
end-stage HF samples that co-localize with the ER (te Rijdt et al,
2016, 2017) and that also stained positive for RCN-3. Notably, TEM
performed in HF samples provided evidence that the aggregates are
in fact aggresomes and contain misfolded proteins when the protein
degradation system of the cell is overwhelmed (te Rijdt et al, 2016,
2017). The presence of aggresomes thus reflects ER dysfunction
(Scior et al, 2016), consequently supporting our findings.
The close interaction between ER and mitochondria is one impor-
tant aspect of the current understanding of ER function via
membrane contact sites (MCS) (Phillips & Voeltz, 2016). Other







Figure 8. Effect of Ca2+-scavenging.
A–D Western immunoblots for pAMPK at Thr172 and pPDH at Ser293 for PLNic and PLN p.Arg14del transduced with control, GCaMP6f or parvalbumin virus, n = 6–9,
each replicate consists of a pool of 2–3 EHTs. Two-way ANOVA (comparing genotypes and virus conditions) with Sidak’s post-test, mean  SEM, *P < 0.05. C:
control virus, G: GCaMP6f virus, and P: parvalbumin virus.
E Force of PLNic and PLN p.Arg14del spontaneous beating EHTs on day 30 of EHT development, replicate numbers are PLNic: control virus: n = 24, GCaMP6f: n = 23,
and parvalbumin: n = 24; and PLN p.Arg14del: control virus: n = 22, GCaMP6f: n = 24, and parvalbumin: n = 22; EHTs were from 2 different batches. Two-way
ANOVA (comparing genotypes and virus conditions) with Sidak’s post-test, mean  SEM, *P < 0.05.
F–H Quantitative PCR of ER/UPR stress marker genes. PLNic and PLN p.Arg14del EHT after transduction with a control virus, or a virus encoding for GCaMP6f or
parvalbumin; n = 6; each replicate consists of a pool of 2–3 EHTs. Two-way ANOVA (comparing genotypes and virus conditions) with Sidak’s post-test,
mean  SEM, *P < 0.05.
I, J Immunofluorescence of 2D hiPSC-CM from PLNic and PLN p.Arg14del after transduction with control, GCaMP6f, or parvalbumin virus with antibodies recognizing
PLN (red), 8-OHdG (green), and DAPI staining for nuclei (blue); scale bar 20 µm.
Source data are available online for this figure.
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important organelles that interact via ER-MCS are endosomes and
Golgi vesicles, which are involved in the formation of lysosomes,
phagosomes, and peroxisomes, also contributing to the degradation
of misfolded proteins. Notably, reduced representation of KEGG path-
ways for lysosome, phagosome, and peroxisome pathways empha-
sized that the ER-MCS with these organelles could also be affected
and thus further contribute to the deterioration of the PLN p.
Arg14del cardiomyopathy. The relevance of these findings is strength-
ened by histological staining of explanted human ventricular heart
tissue. Alteration of three protein candidates from the proteomic
screen and enhanced oxidative stress were confirmed in left ventricu-
lar cardiac tissue from a patient with PLN p. Arg14del end-stage HF.
What is the link between a mutation in PLN and a dysfunctional
ER/mitochondria compartment? Often overlooked when studying
cardiomyocyte function is that PLN not only regulates SERCA2a and
Ca2+ re-entry into the SR, but also importantly ascertains unper-
turbed Ca2+ flux between the ER and the mitochondria. In principle,
altered protein conformation of a dysfunctional mutant protein
could directly affect localization and interaction of proteins
crucial for ER/mitochondria integrity. Thus, it could, in a SERCA2-
dependent or independent manner, alter Ca2+ handling in a compart-
ment critical for the functional integrity of ER-mitochondria interac-
tion. Alternatively, haploinsufficiency and degradation of the
mutant PLN protein could contribute to the disease phenotype. This
hypothesis is supported by our data showing reduced PLN protein
abundance by IF and proteomic analysis. An important focus of
future studies is therefore to unequivocally determine whether the
mutant PLN protein is expressed or immediately degraded by the
UPR. Our data unveiled an unexpected beneficial action of Ca2+
scavenging. Heterologous expression of Ca2+-buffering proteins
improved the PLN p. Arg14del disease phenotype as evidenced by
an amelioration of functional, structural, and molecular abnormali-
ties in PLN p. Arg14del EHTs.
In essence, the present study postulates PLN p. Arg14del-
mediated dysfunction of the ER/mitochondria compartment as a
novel molecular disease mechanism. This discovery opens new
avenues for therapeutic intervention and target identification. The
direct causal involvement of Ca2+ irregularities and the beneficial
effect of Ca2+ scavenging are indicative of the potential for cytoplas-
mic Ca2+ buffering as a promising therapeutic approach. This inter-
connects the pathology evoked by PLN p. Arg14del mutation with
ongoing scientific discussions to optimize cytoplasmic Ca2+
buffering as a treatment strategy in patients (Smith & Eisner, 2019).
Materials and Methods
Ethical approval
All human samples used in the present study were obtained after
informed written consent by the patients. All experiments conformed
to the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont report (ethics
agreement reference number NL30225.018.09; ethics commission
Ruhr-Universit€at Bochum, reference number Reg.-Nr. 21.1/2013;
University Utrecht protocol numbers: 12/387 and 15/252; Ethical
Committee of the University Medical Center Hamburg-Eppendorf,
reference number 532/116/9.7.1991).
Reprogramming
A skin biopsy was taken from a PLN p. Arg14del mutation carrier diag-
nosed with familial DCM under local anesthesia after signature of
informed consent (ethics agreement reference number NL30225.018.09).
After washing in PBS, the skin piece was minced and placed in a
T25 flask (Sarstedt) in fibroblast medium (DMEM with 10% FBS
(PAA), 2 mM L-glutamine, and 0.5% penicillin and streptomycin
(all Life Technologies)). Dermal fibroblasts growing out of the
explants were cultured in a monolayer, expanded, and repro-
grammed at passage 5 according to the previously published proto-
cols (Takahashi et al, ,2007a, 2007b; Ohnuki et al, 2009). As
described therein, transduction efficiency of the fibroblasts was
improved by first introducing the mouse receptor for retroviruses
Slc7a1 (encoded by pLenti6-Ubc-mSlc7a1). Subsequently, the
human transcription factors OCT3/4, SOX2, KLF4, GLIS-1, and p53
shRNA were introduced with ecotropic retroviruses (encoded by
pMXs-plasmids available from Addgene). All virus productions
were performed in Plat-E packaging cells (Takahashi et al, 2007a)
with retroviruses encoding the human transcription factors OCT3/
4, SOX2, KLF4, GLIS-1, and p53 shRNA. Five days after transduc-
tion, dermal fibroblasts were harvested by trypsinization and re-
plated at 8 × 104 cells/10 cm2 on mitotically inactivated mouse
embryonic fibroblasts (MEF strain CF-1). On the following day, the
fibroblast medium was replaced by MEF-conditioned medium (sup-
plemented with 10 ng/ml bFGF) followed by consecutive daily
medium change. HiPSC clones were picked and transferred to
MatrigelTM-coated 48-well plates approximately 4 weeks after
transduction and further expanded and cultured using the standard
procedure (Breckwoldt et al, 2017).
Karyotyping, mycoplasma
Karyotype and pluripotency analysis of hiPSC clones in master cell
bank and mycoplasma screen of master cell bank and expanding
hiPSCs was performed as recently described (Breckwoldt et al, 2017).
Expansion and differentiation of human-induced pluripotent
stem cells
Experiments were performed as recently described (Breckwoldt et al,
2017). In brief, hiPSCs were expanded from a master cell bank at
passage 30–40 (PLN p. Arg14del) and passage 56–61 (PLNic) on
Geltrex-coated cell culture flasks in FTDA. Formation of embryoid
bodies was performed in spinner flasks, and differentiation was
conducted in Pluronic F-127-coated cell culture flasks with a sequen-
tial administration of growth factor- and small molecule-based cocktails
to induce mesodermal progenitors, cardiac progenitors, and cardiomy-
ocytes. Dissociation of differentiated cardiomyocytes was performed
with collagenase II (200 units/ml; Worthington, LS004176). Dissociated
cardiomyocytes were analyzed for cardiac differentiation efficiency
(cardiac troponin T) as recently described and subjected to EHT genera-
tion or 2D culture (Breckwoldt et al, 2017).
Immunofluorescence staining of hiPSC
HiPSCs were rinsed briefly in 1x PBS and fixed for 15 min with 4%
paraformaldehyde at room temperature. The hiPSCs were washed
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three times with PBS for 5 min and incubated in blocking solution
for 1 h at room temperature. Primary antibody incubation (Oct-4A
or TRA-1-60(S) [Cell Signaling], 1:200 in antibody dilution buffer)
was carried out overnight at 4°C in a humid chamber. The following
day, the hiPSCs were washed three times with 1× PBS and incubated
for 1 h at room temperature with the secondary antibody (Alexa
Fluor 546 goat anti-rabbit IgG, 1:500 in antibody dilution buffer or
Alexa Fluor 488 goat anti-mouse IgM µ chain, 1:500 in antibody
dilution buffer, Molecular Probes Invitrogen) and DAPI for nuclear
staining. After the final three PBS washing steps, the cells were
mounted, analyzed, and stored at 4°C in the dark.
Immunofluorescence of hiPSC-CM and microscopy
Prior to staining, hiPSC-CMs were fixed with 4% paraformaldehyde
(PFA) in PBS for 10 min with two intermediate washing steps in
200 µl PBS/well and subsequently covered with parafilm and stored
at 4°C in PBS until further processing.
For immunofluorescent staining of hiPSC-CM, PBS was removed
and cells were permeabilized with either 0.2% Triton X-100 (Roth
3051.3) or 0.2% saponin (Sigma, S7900, from quillaja bark) in PBS for
5 min at room temperature (RT) followed by a washing step in 200 µl
PBS/well for 5 min. Subsequently, non-specific binding sites were
blocked with 5% Normal Goat Serum (NGS) for 20 min at RT. For the
primary antibody incubation, cells were incubated overnight with
50 µl/well of the primary antibodies phospholamban (1:100, rabbit,
Novus Biologicals, NBP2-19807), SERCA2 (1:100, mouse, Invitrogen,
MA3-919), anti-8-hydroxy-20-deoxyguanosine (8-OHdG, 1:50, mouse,
Abcam, ab48508), GFP-FL (1:100, rabbit, Santa Cruz Biotechnology,
sc-8334), calnexin (1:100, mouse, Novus Biologicals, AF18), VDAC1
(1:100, mouse, Abcam, ab14734), parvalbumin (1:100, rabbit, Abcam,
ab181086) and a-actinin (1:500, mouse, Sigma, A7811) or a-actinin
(1:500, rabbit, Sigma, A2543) diluted in antibody buffer (10 mM Tris,
155 mM NaCl, 2 mM EGTA, 2 mM MgCl2, 1% (w/v) BSA, pH 7.5) at
4°C in a humid chamber under shaking. After three washing steps
with 200 µl PBS/well, cells were incubated with 50 µl secondary anti-
body solution consisting of the secondary antibodies Alexa Fluor 647
goat anti-mouse (1:100, Invitrogen, A21236), Goat anti-rabbit
DyLight 550 (1:100 DyLight 550, Abcam, ab96884), and 40,6-
diamidino-2-phenylindole (DAPI, 1:100, Sigma, D9542) in a humid
chamber on a shaker for 3h at RT. For staining of lipids, BODIPY
(10 µM final concentration, D3911, Invitrogen) was added 30 min
prior to the end of incubation with secondary antibodies. Thereafter,
another five washing steps with 200 µl PBS/well were performed
under agitation, and the 96-well plate was covered with parafilm and
stored at 4°C until microscopy. The imaging system consisted of a
Zeiss LSM 800 Airyscan confocal microscope, and the images were
recorded using a 40× or 63× oil immersion objectives.
In situ proximity ligation assay
Interactions between the ER and mitochondria were analyzed using
an in situ proximity ligation assay (PLA). With this method, each
distinct fluorescent spot represents an interaction between VDAC1
and IP3R. Briefly, hiPSC-CMs were fixed with 4% PFA in PBS for
10 min at RT. After two intermediate washing steps in 200 µl PBS/
well, the plates were subsequently covered with parafilm and stored
at 4°C in PBS until further processing. For permeabilization, cells
were incubated in 100 µl 0.1% Triton X-100 PBS for 15 min at RT
under agitation followed by one washing step in 200 µl PBS/well for
5 min. Non-specific binding sites were blocked for 30 min at 37°C
in a humidity chamber with 100 µl of the blocking solution that was
provided by the kit (Sigma, DUO92002). After removal of the block-
ing solution, the cells were incubated with the primary antibody
combination VDAC (1:100, mouse, Abcam, ab14734) and IP3R
(1:500, rabbit, Abcam, ab5804) diluted in antibody buffer (10 mM
Tris, 155 mM NaCl, 2 mM EGTA, 2 mM MgCl2, 1% (w/v) BSA, pH
7.5) at 4°C in a humidity chamber on a shaker overnight. Negative
controls were only incubated in antibody buffer without primary
antibodies.
According to the manufacturer’s instructions, the secondary anti-
bodies conjugated either with the oligonucleotide PLA probe PLUS
(Sigma, DUO92002) or with the oligonucleotide PLA probe MINUS
(Sigma, DUO92004) were diluted 1:5 in the Duolink antibody dilu-
ent and allowed to incubate for 20 min at RT before usage. The
primary antibody solutions were removed, and cells were washed
twice in 200 µl 1× wash buffer A (Sigma, DUO82049) at RT under
agitation followed by incubation with 40 µl/well of the PLA probe
solution. The plates were then incubated in a pre-heated humidity
chamber for 1 h at 37°C. The negative controls were incubated with
either the PLA probe PLUS or the PLA probe MINUS.
Subsequently, the cells were washed twice with 200 µl wash
buffer A for 5 min at RT followed by incubation for 30 min at 37°C
in a pre-heated humidity chamber with a ligation solution (Sigma,
DUO92007), consisting of two oligonucleotides and a ligase that
hybridize the oligonucleotides to the two PLA probes if the distance
between the targeted proteins is < 40 nm. The oligonucleotide of
one of the PLA probes is then used as a primer for a rolling-circle
amplification (RCA) enabling binding of fluorescently labeled
oligonucleotides to the RCA product. For this amplification, cells
were washed twice in 200 µl 1× wash buffer A for 5 min at RT and
incubated in a pre-heated humidity chamber for 100 min at 37°C
with 40 µl of an amplification solution provided by the kit (Sigma,
DUO92007).
For counterstaining of the nuclei, the amplification solution was
removed, and cells were washed twice in 200 µl 1× wash buffer B
(Sigma, DUO82049) for 10 min at RT and for 1 min in 200 µl 1×
wash buffer A and incubated with DAPI (1:100) in antibody buffer
for 40 min at RT in a humidity chamber under agitation. Afterward,
the cells were washed twice for 2 min with 1× wash buffer A and
once with 200 µl 0.01× wash buffer B for 1 min and stored in PBS
until microscopy. The imaging system consisted of a Zeiss LSM 800
Airyscan confocal microscope, and the images were recorded using
a 40× oil immersion objective.
Lentivirus production
To express the Ca2+ sensor Fast-GCaMP6f-RS09 under control of the
EF1a promoter together with a puromycin resistance, the lentiviral
vector LeGO-EF1a i-Pur2 (derived from Addgene plasmid #27341
LeGO-iG2) was digested with BamHI and NotI. PCR was performed
using Phusion polymerase and plasmid Fast-GCaMP6f-RS09
(Addgene 67160) as a template encoding GCaMP6f with an N-
terminal 6× His Tag, a T7 Tag and an Xpress Tag with the following
primer pair: 50-GTCGTGAGGAATTCGGATCCaccATGGGTTCTCATC
ATCATCATCATC and 50- ATTTACGTAGCGGCCGCTTACTTCGCTG
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TCATCATTTGTAC. PCR product and digested plasmid LeGO-EF1a
i-Pur2 were incubated with 5X In-Fusion HD Enzyme Premix (In-
Fusion HD Cloning Kit, Clontech) according to the recommendations
of the manufacturer. Resulting clones were checked by restriction
digest, PCR and were finally verified by sequencing. To express
human parvalbumin (Homo sapiens parvalbumin (PVALB), tran-
script variant 2, mRNA; NCBI Reference Sequence: NM_001315532.2)
under control of a ubiquitous EF1a promoter, a gene block was
designed (Integrated DNA Technologies, IDT). This gene block
comprised 50-overhangs of 15 bp each homologous to the lentiviral
plasmid LeGO-EF1a-iPur2 (kind gift from Boris Fehse, University
Medical Center Hamburg-Eppendorf, Hamburg, Germany). After
digestion of LeGO-EF1a-iPur2 with BamH I and Not I, both linear-
ized plasmid and gene block were assembled using the In-Fusion
Cloning Kit (Takara Clontech), generating LeGO-EF1a-huPVALB-
iPur2. Resulting expression clones were checked by restriction
digest, PCR and were finally verified by sequencing. Stocks of VSV-
G pseudotyped viral particles were produced at the Vector Facility
of the University Medical Center Eppendorf using lentiviral transfer
plasmid LeGO-EF1a-huPVALB-iPur2 and packaging plasmids
psPAX2 (Addgene plasmid #12260) and pMD2.G (Addgene plasmid
#12259). LeGO-EF1a-iPur2 was employed to produce negative
control lentivirus. After concentration by ultracentrifugation for 2 h
at 4°C (140,000 g, SW32Ti rotor) on a 20% sucrose cushion, the
pellet was resuspended in DPBS. The functional titer was deter-
mined by transduction of HEK293T and quantification by flow
cytometry (FACSCantoII, BD Biosciences; FITC Channel).
CRISPR/Cas9
PLN p. Arg14del mutation was verified in patient-derived hiPSCs by
Sanger sequencing (Eurofins MWG Operon). For the generation of
the isogenic controls, the CRISPR/Cas9 system derived from Strepto-
coccus pyogenes (Sp) was applied. Identification of suitable PAM
sequences and the design of the 20-nt long sgRNA were done with
the online CRISPR design web tool provided by the Zhang labora-
tory (MIT, 2015; https://zlab.bio/guide-design-resources, CAAC-
CATTGAAATGCCTCAA). The repair template was designed as a
103-nt long single stranded oligonucleotide (ssODN CTGCTGGTAT
CATGGAGAAAGTCCAATACCTCACTCGCTCAGCTATAAGAAGAGCA
TCAACCATTGAAATGCCTCAACAAGCACGTCAAAAGCTACAGAATCT)
encoding the PLN WT sequence and carrying a silent mutation in
the PAM sequence to avoid WT Cas9 cleavage of the ssODN. The
ssODN was used in antisense direction as a 4 nmol Ultramer DNA
Oligo with standard desalting purification from Integrated DNA
Technologies (IDT). The sgRNA was cloned into the pSpCas9(BB)-
2A-GFP vector (Addgene, plasmid ID: 48138) according to the proto-
col published (Ran et al, 2013). For the ribonucleoprotein (RNP)
approach, a 120 bp long sgDNA construct was designed encoding a
T7 promoter preceding the sgRNA sequence. The sgRNA was gener-
ated by in vitro transcription with the High Scribe T7 quick HI yield kit
(E2050, NEB) according to the manufacturer’s instructions and cleaned
up with the Ambio MegaClear kit (AM1903). The sgRNA was precipi-
tated with ethanol and reconstituted in sterile PBS (stock concentra-
tion: 10 µg/µl). Recombinant GeneArtTM PlatinumTM Cas9 nuclease
(Thermo Fisher Scientific/Invitrogen, B25641) was used.
PLN p. Arg14del hiPSCs were expanded in conditioned medium
(murine embryonic fibroblasts) until 90–100% confluency. Two
hours before nucleofection, hiPSCs were incubated with Y-27632
(10 µM) and bFGF [30 ng]. HiPSCs were dissociated with Accu-
tase into single cells (5 min, 37°C). For nucleofection, 0.8x106
hiPSCs were resuspended in 100 µl “P3 solution” (prepared by
mixing 82 µl “Nucleofector solution” plus 18 µl supplement)
according to the manufacturer’s instructions (Lonza). For the DNA-
based approach, 2 µg pSpCas9-sgRNA-2A-GFP plasmid and 5 µM
ssODN repair template were mixed with the 100 µl cell suspension
and transferred to the Amaxa nucleofection cuvette. For the RNP
approach, 18 µg Cas9 was complexed with 4 µg sgRNA for 10 min
at room temperature. Repair template (final concentration 5 µM)
and the Cas9/sgRNA complex were mixed gently and the mixture
was added to the 100 µl cell suspension into an Amaxa nucleo-
fection cuvette. Nucleofection was performed with the 4D-
NucleofectorTM (Lonza) according to the manufacturer’s instruc-
tions. Nucleofection program CA-137 was applied. After nucleofec-
tion, the cells were incubated for 5 min in the cuvette at 37°C.
HiPSC were plated on MatrigelTM-coated 12-well culture dishes
(0.8 × 106 hiPSC per well) in conditioned medium supplemented
with Y-27632 (10 µM). Medium was changed after 24 h. After 48 h,
pSpCas9-sgRNA-2A-GFP-nucleofected hiPSCs were dissociated with
Accutase (5 min, 37°C), centrifuged (5 min, 200 ×g), and resus-
pended in PBS. GFP-positive cells were separated by FACS (drop
rate of 1–2, nozzle of 100 µm, BD FACSAriaTM Fusion) under sterile
conditions, collected in conditioned medium with Y-27632 (10 µM),
and plated in Matrigel-coated 6-well plates at 1.0–1.5 × 103 cells per
well. For the RNP approach, nucleofected hiPSCs without prior
FASC sorting were plated at a density of 3.0 × 103 cells/well. After
10–14 days of hiPSC expansion, individual clones were picked
(10 µM Y-27632 1 h prior to picking) and transferred to 48- and
subsequently 24-well dishes. Copy plates in the 24-well format were
generated, and aliquots were frozen. DNA was isolated and
sequenced to test the genome editing efficiency as well as to
exclude modification of the 10 most probable off-target loci.
Suitable isogenic control clones were chosen and sent for kary-
otyping. Both isogenic controls were used for the functional experi-
ments in this study.
Quantitative PCR
The reverse transcription of RNA to cDNA was performed with the
“High Capacity cDNA Reverse Transcription Kit” (Applied Biosys-
tems) according to the manufacturer’s instructions. The qPCR was
performed with SYBR Green (Thermo Fisher Scientific) in technical
duplicates. The cardiac-specific housekeeping gene a-Actinin 2
(ACTN2) and glucuronidase-beta (GUSB) were used as reference
transcripts for normalization. The target sequences were amplified
within 40 cycles in an AbiPrism7900HT cycler (Applied Biosystems)
according to the manufacturer’s instructions. The following primer
pairs were used: PLN (NM_002667.3), PLNwt/mut-for 50-CAA
TACCTCACTCGCTCAGC-30, PLNwt/mut-rev: 50-AGAGAAGCATCAC
GATGATACAG-30. PLNwt-for 50-CTCGCTCAGCTATAAGAAGAGC-30,
PLNwt-rev: 50-AGAGAAGCATCACGATGATACAG-30. PLNmut-for 50-
CACTCGCTCAGCTATAAGAGC-30, PLNmut-rev: 50-AGAGAAGCATC
ACGATGATACAG 30, ACTN2 (NM_001103.3, NM_001278344.1,
NM_001278343.1), ACTN2-for 50-AAGGGGTGAAACTGGTGTCC-30,
ACTN2-rev: 50-AGCAGACCTTCTTTGGCAGAT-30. Primer pairs were
adapted from Karakikes et al, (2015). Left ventricular heart samples
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were collected after signature of informed consent (ethics commis-
sion Ruhr-Universit€at Bochum, reference number Reg.-Nr. 21.1/
2013). Endoplasmic reticulum stress response genes analysed were
recently described in Sicari et al (2020) (XBP1 splice variant -forward
TGCTGAGTCCGCAGCAGGTG, -reverse: GCTGGCAGGCTCTGGGGA
AG; CHOP -forward: CAGAACCAGCAGAGGTCACA, -reverse AGCT
GTGCCACTTTCCTTTC; SCARA3 -forward: CGCTGCCAGAAGAACC
TATC, -reverse AACCAGAGAGGCCAACACAG, BIP -forward: TGT
TCAACCAATTATCAGCAAACTC, -reverse, TTCTGCTGTATCCTCTT
CACCAGT; PDIA4 -forward: AGTGGGGAGGATGTCAATGC, -reverse
TGGCTGGGATTTGATGACTG; HYOU1 -forward: GCAGACCTGTTGG
CACTGAG, -reverse TCACGATCACCGGTGTTTTC). Fetal gene program
PCR primers used were as follows: (MYH6 –forward: TCTTCTC
CTCCTACGCAACTG, -reverse TTGAGATTTTCCCGGTGGAGAG; MYH7
–forward: GCTCTGTGTCTTTCCCTGCTGCTC, -reverse GCTCCTTC
TCTGACTTGCGCAGG; COL1A1 –forward: GGGAATGCCTGGTGA
ACGTG, -reverse CCTTGTCACCAGGGGCAC; NPPA –forward: GCT
GCTTCGGGGGCAGGATG, -reverse TGCAGCAGAGACCCCAGGGG).
Quantification of reactive oxygen/nitrogen species
Reactive oxygen and reactive nitrogen species (ROS/RNS) content
was determined using the OxiSelectTM in vitro ROS/RNS Assay Kit
(STA-347, Cell Biolabs, Inc., San Diego, CA) according to the manufac-
turer’s instructions. For comparison of ROS/RNS in medium super-
natant, EHTs were cultured for 24 h in 1.5 ml complete medium, of
which 500 µl medium was centrifuged. Supernatant was snap-frozen
in 80°C and thawed in a water bath at 37°C directly before the assay
was conducted. Intracellular free radical content was measured after
dissociating EHTs into single cells with papain and homogenization of
1 x106 cells (pool of 4 EHTs, 48 technical, 8 biological replicates, three
independent experiments) in 100 µl in PBS, and supernatant was
snap-frozen after centrifugation and stored at 80°C until the assay
was conducted. Fluorescence measurement was performed with a
485/538 nm filter set on a FluoroCount Plate Reader (Packard). Stan-
dard curves were constructed with dichlorofluorescin and hydrogen
peroxide and prepared according to the manufacturer’s instructions.
Quantitative PCR mitochondria
Total and mitochondrial DNA was extracted using the DNeasy Blood
& Tissue Kit (69506, Qiagen) following the manufacturer’s protocol.
Quantitative PCR was performed on the AbiPrism 7900HT Fast Real-
Time PCR System (Applied Biosystems) utilizing SYBR Green/ROX
qPCR Master Mix (K0222, Thermo Scientific). Primer sequences for
mitochondrial DNA were as follows: mtND1 (Gene ID: 4535), mt-
ND1for: 50-ATGGCCAACCTCCTACTCCTCATT-30, mt-ND1rev: 50-TT
ATGGCGTCAGCGAAGGGTTGTA-30; mtND2 (Gene ID: 4536), mt-
ND2for: 50-CCATCTTTGCAGGCACACTCATCA-30; mt-ND2rev: 50-AT
TATGGATGCGGTTGCTTGCGTG-30; ACTB (NM_001101) (actin, beta)
_for: 50-CATGTACGTTGCTATCCAGGC-30, ACTB_rev: 50-CTCCTT
AATGTCACGCACGAT-30. Primer sequences as described (Ulmer
et al, 2018).
Analysis of mitochondrial respiration
The SeahorseTM XF96 extracellular flux analyzer was used to assess
mitochondrial respiration as previously described (Mosqueira et al,
2019), using the Mito Stress Kit (Agilent Technologies). Briefly,
cryopreserved isogenic sets of hiPSC-CMs were seeded into Matri-
gelTM-coated (BD #356235) XF96-well plates at a density of approxi-
mately 5000 cells/mm2. HiPSC-CMs were cultured for 2 days in
RPMI1640 (US Biological Life Sciences #R9010-01) supplemented
with B-27 with insulin (Life Technologies #0080085-SA), 2 mM L-
glutamine (Life Technologies #25030-081), 10% fetal bovine serum
(Gibco #16000044), and 0.6 mM CaCl2. After 2 weeks, medium was
exchanged for XF basal medium (Agilent Technologies #102353),
supplemented with 10 mM glucose (Sigma #G7528), 1 mM sodium
pyruvate (Sigma #S8636), and 2 mM L-glutamine (Life Technologies
#25030-081) 1 h prior to conduction of the assay. Selective inhibi-
tors were sequentially injected during the measurements (1.5 lM
oligomycin, 0.4 lM FCCP, 1 lM rotenone; Agilent Technologies),
following the manufacturer’s instructions. The measured oxygen
consumption rate (OCR) values were normalized to the number of
cells in each well, quantified by 1:400 Hoechst 33342 staining
(Sigma #B2261) in PBS (Gibco #14190-094) using fluorescence at
355 nm excitation and 460 nm emission in an automated imaging
platform (CellaVista, Synentec). Statistical analysis was performed
by using GraphPad Prism (v7, La Jolla, CA, USA) software, evalu-
ated by unpaired one-way ANOVA test followed by Tukey post hoc
test for correction of multiple comparisons, and differences were
considered significant when *P < 0.05.
Assessment of protein carbonylation
Detection of protein carbonylation in PLNic and PLN p. Arg14del
hiPSC-CM was assessed using the Protein Carbonyl Assay Kit
(Abcam #ab178020) according to the manufacturer’s instructions. In
brief, 2D hiPSC-CMs were washed with PBS and harvested in extrac-
tion buffer containing 50 mM DTT. Proteins were denatured by SDS
and incubated with 2,4-dinitrophenylhydrazine (DNPH) or control
derivatization solution for 15 min. The reaction was stopped by
addition of neutralization buffer. Protein samples were separated by
10% SDS–PAGE, blotted onto nitrocellulose, and blocked in 10%
non-fat milk in TBS-T. Membranes were probed with an anti-DNP
antibody (1:5,000 in blocking buffer). Equal protein loading
between DNPH and control-derivatized samples was ascertained by
probing with an antibody against cMyBP-C. Proteins that underwent
oxidation were detected by the anti-DNP antibody, only in the
DNPH-derivatized samples.
Western immunoblot analysis
For Western immunoblot analysis, EHTs were homogenized in 1x
Mammalian Protein Extraction Reagent (M-PER; Thermo Fisher
Scientific) supplemented with phosphatase inhibitor PhosSTOP
(Sigma-Aldrich) and protease inhibitor cOmplete (Roche). Thereby,
70 µl of lysis buffer was used per EHT and 3–4 EHTs were pooled
per sample. Homogenization was performed in a TissueLyser (Qia-
gen) using a metal bead. Samples were boiled at 95°C for 5 min.
EHT homogenate samples were separated by SDS–PAGE (7.5–12%)
and transferred to polyvinylidene difluoride (PVDF) or nitrocellulose
membrane. After blocking non-specific binding sites with 10% (w/
v) non-fat skimmed milk or 5% bovine serum albumin in 0.1% (v/
v) Tween 20-TBS (Tris 20 mM, NaCl 137 mM; pH 7.6), membranes
were incubated overnight at 4°C with primary antibodies (dilution
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1:1,000–1:5,000), followed by horseradish peroxidase (HRP)-
conjugated secondary antibody incubation on the next day (dilution
1:2,000). Specific protein bands were detected by enhanced chemi-
luminescence (GE Healthcare) on a ChemiDoc (Bio-Rad) and quanti-
fied using the Gene Tools software (Syngene). Primary antibodies
used were as follows: alpha-actinin (1:1,000, Sigma-Aldrich,
A7811), phospholamban (1:1,000, Novus, NBP2-19807), phospho-
lamban pSer16 (1:5,000, Badrilla, A010-12AP), pyruvate dehydroge-
nase (phospho S293) (Abcam, ab177461), pyruvate dehydrogenase
(Abcam, ab168379), AMPK (phospho threonine 172) (Cell Signaling
Technology, CST 2535), AMPKa (Cell Signaling Technology, CST
D5A2), galectin-3 (Thermo Fisher, MA1-940), reticulocalbin-3
(Abcam, ab204178), LMCD1 (Thermo Fisher, MA5-25603), SAFB-
like transcription modulator (Novus Biologicals, NBP2-38464), and
calnexin (Novus Biologicals, AF18). Left ventricular heart samples
were collected after informed consent (Ethical Committee of the
University Medical Center Hamburg-Eppendorf, reference number
532/116/9.7.1991).
Immunohistochemistry
The study met the criteria of the code of proper use of human tissue
that is used in the Netherlands. The collection of the human heart
tissue used for immunohistochemistry was approved by the advi-
sory board of the biobank of the University Medical Center Utrecht,
Utrecht, the Netherlands (protocol numbers: 12/387 and 15/252).
Written informed consent was obtained or in certain cases waived
by the ethics committee when obtaining informed consent was not
possible due to death of the patient. For immunohistochemistry 3
PLN p. Arg14del explanted hearts, 3 explanted hearts with end-stage
ischemic heart disease (remote area) and 3 healthy control hearts
obtained during autopsy of patients that had died due to a non-
cardiac cause were used. Sections were either pretreated with EDTA
or boiled in citrate buffer. Primary antibodies used were as follows:
PLN (Badrilla, A010-10AP), reticulocalbin-3 (Abcam, ab204178),
LMCD1 (Atlas Antibodies, HPA024059), SAFB-like transcription
modulator (Novus Biologicals, NBP2-38464), and anti-8-hydroxy-20-
deoxyguanosine (Abcam, ab48508). BrightVision Poly-AP-Anti
mouse or rabbit IgG (Immunologic) was used as secondary anti-
body, and the signal was visualized with liquid permanent red
(Dako). Quantification of 8-hydroxy-20-deoxyguanosine (8-OHdG),
reticulocalbin-3 (RCN3) aggregate-type formation was performed by
two persons under blinded conditions.
Transmission electron microscopy
EHTs were fixed in a mixture of 4% paraformaldehyde and 1%
glutaraldehyde (Science Services, Germany) in 0.1 M phosphate
buffer overnight at 4°C. Samples were rinsed three times in 0.1 M
sodium cacodylate buffer (pH 7.2–7.4) and osmicated using 1%
osmium tetroxide in cacodylate buffer. Following osmication, the
samples were dehydrated using ascending ethanol concentrations,
followed by two rinses in propylene oxide. Infiltration of the embed-
ding medium was performed by immersion in a 1:1 mixture of
propylene oxide and Epon (Science Services, Germany), followed by
neat Epon and hardening at 60°C for 48 h. For light microscopy,
semi-thin sections (0.5 µm) with longitudinal orientation were
mounted on glass slides and stained for 1 min with 1% toluidine
blue. For electron microscopy, ultra-thin sections (60 nm) were cut
and mounted on copper grids and stained using uranyl acetate and
lead citrate. Sections were examined and photographed using an
EM902 (Zeiss) electron microscope equipped with a TRS 2K digital
camera (A. Tröndle, Moorenweis, Germany).
EHT generation and maintenance, contractility recording
EHTs were generated from dissociated hiPSC-CM in a matrix from
fibrinogen and thrombin as previously described, with 1 × 106 cells
per EHT (Breckwoldt et al, 2017). EHTs were maintained in 24-well
cell culture dishes in 1.5 ml EHT medium that was exchanged every
second day. EHTs were subjected to force analysis between days 18
and 33 after casting. EHTs were fixed in formalin (4%) or snap-
frozen in liquid nitrogen for DNA, RNA, or protein analysis.
Contractility analysis in EHTs was performed by video-optical
recording as described previously (Breckwoldt et al, 2017). Electri-
cal pacing was performed with graphite pacing systems as recently
described (Mannhardt et al, 2016). Contractility recording under
serum free conditions was performed in modified Tyrode’s solution
(120 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 0.1–5 mM CaCl2, 0.4 mM
NaH2PO4, 22.6 mM NaHCO3, 5 mM glucose, 0.05 mM, Na2EDTA,
25 mM HEPES) pre-equilibrated overnight (37 °C, 7% CO2, 40% O2,
53% N2).
Assessment of Ca2+ transients in 2D hiPSC-CM
PLNic and PLN p. Arg14del hiPSC-CM were seeded onto gelatin-
coated glass coverslips (24x24 mm, VWR) in a 6-well culture dish at
a density of 2 × 105 hiPSC-CM per dish (10 cm2). The hiPSC-CMs
were cultured for 7  2 days (RPMI, B-27) until analysis. 2.5 µM
Fura 2-AM (5 mM stock in DMSO) was dissolved in 2 ml Tyrode’s
solution for 2D Ca2+ transient analysis. The cardiomyocytes were
washed with 2 ml Tyrode’s solution and loaded with Fura 2-AM for
15 min protected from light. The Fura 2-AM-containing buffer was
replaced by 3–4 ml Tyrode’s solution for a 15-min washing step.
The coverslips with the hiPSC-CM were removed from the culture
wells for analysis with the IonOptix system (IonOptix, Milton, USA).
The cells were continuously superfused with 37°C pre-warmed
Tyrode’s solution and paced at 0.5 Hz. Cells were included into the
analysis, when they showed a regular beating pattern and followed
the electrical pacing signal. Furthermore, cells should be either in a
single or in a small cell cluster format (3–5 cells), but not part of
larger cell aggregates. Initially, a stable baseline was recorded. Elec-
trical stimulation was switched off, and 20 mM caffeine was applied
to the cells. After 10–15 s, the perfusion was switched back to
normal Tyrode’s solution and cells were electrically stimulated
again. The recording was continued for approximately 30 s. A maxi-
mum of three cells per coverslip was recorded.
Proteomic analysis
EHTs from hiPSC-CM were dissociated with collagenase II solution
(collagenase II, 200 units per ml), HBSS minus Ca2+/Mg2+, HEPES
(10 mM), Y-27632 (10 µM), and BTS (30 µM, 4.5 h). Dissociated
hiPSC-CMs were spun down (100 ×g, 5 min), supernatant was
removed, and the pellet was frozen in liquid nitrogen /80°C and
subjected to proteome analysis. Samples were denatured by 6 M
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urea and 2 M thiourea and reduced with 5mM DTT at 37°C for 1 h.
Afterward, proteins were alkylated by 25 mM iodoacetamide and
incubated in the dark for 1 h. Proteins were precipitated by adding
1 ml of ice-cold acetone and precipitated 20°C overnight. Samples
were centrifuged at 16,000× g at 4°C for 30 min, and the super-
natant was discarded. The pellets were dried by SpeedVac (Thermo
Fisher Scientific) for 10 min and resuspended in 0.1 M triethylam-
monium bicarbonate. Samples were digested with trypsin (protein:
enzyme = 50:1) at 37°C overnight. Digestion was stopped by 1% tri-
fluoroacetic acid, and the samples were purified on Bravo
AssayMAP robot (Agilent) using C18 cartridges. Eluted peptides
were SpeedVac dried and resuspended in 2% acetonitrile (ACN),
0.1% formic acid (FA) in LC-MS grade H2O. Peptide samples were
injected and separated by an UltiMate 3000 RSLCnano system
(EASY-Spray column, 75 µm x 50 cm, 2 µm, Thermo Fisher Scien-
tific) using the following LC gradient: 0–10 min: 4–10% B; 10–
75 min: 10–30% B; 75–80 min: 30–40% B; 80–85 min: 40–99% B;
85–90 min: 99% B; 90–120 min: 4% B (A = 0.1% FA in H2O,
B = 80% ACN, 0.1% FA in H2O). The separated peptides were
directly injected into an Orbitrap Fusion Lumos Mass Spectrometer.
Full MS spectra were collected using Orbitrap with scan range 350–
1,500 m/z and a resolution = 120,000. Most abundant ions from full
MS scan were selected for MS2 with CID fragmentation in a linear
ion trap, and cycle time was set to 3 s. Dynamic exclusion of 60 s
and lock mass = 445.12003 m/z were used.
Raw files were processed by Proteome Discoverer 2.2 (Thermo
Fisher Scientific) and searched against UniProt/SwissProt human
database (2018_05, 20349 protein entries) using Mascot 2.6.0.
Trypsin was used for the enzymatic digest, and 2 missed cleavages
were allowed. Carbamidomethylation on cysteines was selected as a
fixed modification and oxidation on methionine as a variable modi-
fication. Precursor ion mass tolerance was set at 10 ppm and for
fragment ion at 0.8 Da. Protein identification FDR confidence was
set to high, and a minimum number of peptides per protein was 2.
Precursor peak area was used for quantification and normalized to
total peak area of each sample and scaled to average 100 across all
samples. The mass spectrometry proteomics data have been depos-
ited to the ProteomeXchange Consortium via the PRIDE (Perez-
Riverol et al, 2019) partner repository with the dataset identifier
PXD020175 and 10.6019/PXD020175.
Before applying enrichment and principal component analysis,
data were further pre-processed with a more advanced processing
and statistical analysis pipeline using the Ebayes algorithm of the
limma package (Smyth). In specific, data were filtered for missing
values. In specific, proteins with more than 30% missing values in
all samples were filtered except the cases where there exist more
than 90% missing values in one subphenotype and less than 10%
missing values in the rest of the subphenotypes. In the latter case,
zeros were imputed in the missing values of the subphenotype
with more than 90% missing values. All remaining missing values
were imputed with KNN-Impute method with k equal to 3 (default
value). The relative quantities of the proteins were scaled using log2
transformation, and P-values were calculated and adjusted by
Benjamini–Hochberg method. Volcano plots were generated with
The R Package Ggplot2 (Wickham, 2009) showing as many signifi-
cantly changing proteins id to avoid overlapping labels. Enrichment
analysis has been conducted using David tool (Huang et al, 2009)
This analysis included pathway terms KEGG (Kanehisa & Goto,
2000). Significant enriched terms were inferred with Benjamini–
Hochberg-adjusted P-value threshold of 0.05.
To visualize the samples based on their proteomic profiles, we
conducted principal component analysis (Jolliffe, 2011), projected
the samples in the 3D space based on their 3 most significant princi-
pal components and colored samples based on their phenotype. The
scikit-learn python library (Pedregosa et al, 2011) version 0.19.2
was used for the PCA, and Scree test (Cattell, 1966) was used to
retain an adequate number of principal components to maintain at
least the 90% variability of the dataset. The protein list was
exported, and further calculations were performed in Excel. Co-
expression networks were constructed using the Aracne-Ap method
(Lachmann et al, 2016). The initial P-values were adjusted for multi-
ple testing using Benjamini–Hochberg method (Ferreira & Zwinder-
man, 2006), and a threshold of 0.05 was used for the adjusted P-
values to infer statistically significant changes.
Transcriptomic analysis
Library preparations and sequencing for RNA-seq
Four stages of differentiation, including undifferentiated hiPSC (day 0),
mesodermal progenitors (day 3), cardiac progenitors (day 8), and
hiPSC-CM (day 15), were analyzed. From these cells, RNA was
extracted by using the Direct-zol RNA MicroPrep Kit (R2060) (Zymo
Research). Libraries for stranded polyA+ RNA sequencing were
prepared using 500 ng total RNA as input in the TruSeq Stranded mRNA
Library Prep Kit (Illumina) following the instructions of the manufac-
turer. Paired-end sequencing was performed using Illumina NovaSeq
6000 System (2 × 50 bp) to a depth of 25 million reads per sample.
Analysis of RNA-seq data
RNA-seq sequencing reads were trimmed for residual adapter
sequences and low-quality 30 ends. For mapping, we used STAR
(v.2.6.1a, default parameters) (Dobin et al, 2013) to align all data-
sets to the human genome (hg38) and to quantify gene expression
per sample, using gene annotations defined by Ensembl v.99. Read
counts were normalized by sample by applying DESeq2’s median of
ratios (Love et al, 2014). We further used DESeq2 to identify
differentially expressed genes between PLN p. Arg14del and
PLNic at each stage of differentiation (P-adjusted < 0.01 and |Fold
Change| ≥ 1.2). We identified enriched KEGG pathways (FDR of
5%) for the sets of differentially up- and downregulated genes by
running gprofiler (Reimand et al, 2016). The generated RNA-seq
datasets are available in the European Nucleotide Archive (ENA)
repository under accession number PRJEB41838.
Ca2+ transients in EHT
Sequential analysis of force and Ca2+ transients was performed on
a microscope stage using GCaMP6f as genetically encoded Ca2+
sensor as recently reported (Saleem et al, 2020). In brief, hiPSC-
CM EHTs were transduced by lentiviral particles (MOI of 0.3)
containing the EF1a promoter—GCaMP6f RS09 plasmid (Addgene
plasmid 67160) during casting. As fluorescent light source, a
mercury lamp was connected to the Axiovert 200 M Zeiss micro-
scope for excitation. A GFP excitation and emission filter set was
used. Sequential analysis of force and Ca2+ transients was
performed in Tyrode’s solution under electrical pacing with
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graphite electrodes in a 24-well culture format (Eppendorf,
030741005) on days 28–36 of EHT development.
Statistical analysis
Data were expressed as means  SEM. GraphPad Prism was used
to compare between groups with Mann–Whitney U-test, unpaired,
two-sided Student’s t-test, and one-way or two-way ANOVA as indi-
cated. Individual hiPSC-CM EHTs or single hiPSC-CM from 9 dif-
ferent differentiation batches from two different clones were
considered as biological replicates. An overview of exact P-values
and number of biological replicates for each experiment is placed in
the manuscript as Appendix Fig S10. Statistical details.
Data availability
Relative quantities of all proteins for the proteomics data of the
paper are provided in Dataset EV1. Code availability: Not applica-
ble. Proteomics data are deposited as a PRIDE partner repository
with the dataset identifier PXD020175 (http://www.ebi.ac.uk/pride/
archive/projects/PXD020175). The RNA-seq datasets are available
in the European Nucleotide Archive (ENA) repository under acces-
sion number PRJEB41838.
Expanded View for this article is available online.
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